Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 4.35+2.8%Dec 17 5:20 PM ESTNews

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Fitzhughlaw who wrote (12159)10/22/2010 9:33:25 AM
From: idahoranch11 Recommendation  Read Replies (1) of 28245
The market pricing in biotech's is all over the map. HGSI was less than 50 cents a share last year, DNDN was under #2.75, I'm sure I could find several examples that would look much like that.

$4 doesn't price ANY of IMMU's pipeline products as being successful, NONE. For that matter, $12 doesn't either, all $12 would suggest is that the market has raised the possibility of success in a product.

I'm not invested in this company for market sentiment. There are those who would buy shares at $3 betting on the greater fool theory, that someone will pay them more than they paid because of past stock action. That is fine, that makes a market, but it doesn't take into consideration an approved hPAM4 or E-mab.

If an offer of $12 or $15 came in, it would be from a company that feels the market is mis-pricing the company, and more than likely it would be offering a low ball number as compared to what it thinks the company is worth.

Since UCB has access to information that we (the market) doesn't, I doubt they could mount a takeover since they would have insider information, just like they probably can't buy shares. They know data we don't know, long term SLE data, etc.

If anyone noticed, on slide #89 in Dr. Leonard's presentation, it said that the ALL trial with E-mab should reach the target enrollment this year. The key primary outcome measure is "Event free survival at 4 months", so it won't take long to finish evaluating the data in this trial, could be by the end of the first quarter of 2011.
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.